Antibodies as Crypts of Antiinfective and Antitumor Peptides

Antibodies (Abs), often associated with antimicrobial and antitumor agents, have emerged as an important class of novel drugs for antigen-driven therapeutic purposes in diverse clinical settings, including oncology and infectious diseases. Abs commonly give rise in the treated host to anti-Ab responses, which may induce adverse reactions and limit their therapeutic efficacy. Their modular domain architecture has been exploited to generate alternative reduced formats (Fabs, scFvs, dAbs, minibodies, multibodies), essentially devoid of the Fc region. The presence of complementarity determining regions (CDRs) ensures the maintenance of selective binding to antigens and supports their use for biotechnological and therapeutic applications. Paradigmatic Abs mimicking the wide-spectrum antimicrobial activity of a yeast killer toxin (killer Abs) have revealed the existence of a family of Abs exerting a direct in vitro and/or in vivo microbicidal activity. Based on the variable sequence of an antiidiotypic recombinant killer Ab, CDR-related peptides have been synthesized, engineered by alanine-scanning and selected according to antimicrobial, antiviral and immunomodulatory properties. Irrespective of the native Ab specificity, synthetic CDRs from unrelated murine and human monoclonal Abs, have shown to display differential in vitro, in vivo and/or ex vivo antifungal (Candida albicans), antiviral (HIV-1) and antitumor (melanoma cells) activities. Alanine substitution of single residues of synthetic CDR peptides resulted in further differential increased/unaltered/decreased biological activity. The intriguing potential of Abs as source of antiinfective and antitumor therapeutics will be discussed, in light of recent advances in peptide design, stability and delivery

Bcl-2 expression and apoptosis induction in human HL60 leukaemic cells treated with a novel organotellurium(IV) compound RT-04

Organotellurium(IV) compounds have been reported to have multiple biological activities including cysteine protease-inhibitory activity, mainly cathepsin B. As cathepsin B is a highly predictive indicator for prognosis and diagnosis of cancer, a possible antitumor potential for these new compounds is expected. In this work, it was investigated the effectiveness of organotellurium(IV) RT-04 to produce lethal effects in the human promyelocytic leukaemia cell line HL60. Using the MTT tetrazolium reduction test, and trypan blue exclusion assay, the IC50 for the compound after 24 h incubation was 6.8 and 0.35 μM, respectively. Moreover, the compound was found to trigger apoptosis in HL60 cells, inducing DNA fragmentation and caspase-3, -6, and -9 activations. The apoptsosis-induced by RT-04 is probably related to the diminished Bcl-2 expression, observed by RT-PCR, in HL60-treated cells. In vivo studies demonstrated that the RT-04 treatment (2.76 mg/kg given for three consecutive days) produces no significant toxic effects for bone marrow and spleen CFU-GM. However, higher doses (5.0 and 10 mg/kg) produced a dose-dependent reduction in the number of CFU-GM of RT-04-treated mice. These results suggest that RT-04 is able to induce apoptosis in HL60 cells by Bcl-2 expression down-modulation. Further studies are necessary to better clarify the effects of this compound on bone marrow normal cells46725402545CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPNão temNão te

Bcl-2 Expression And Apoptosis Induction In Human Hl60 Leukaemic Cells Treated With A Novel Organotellurium(iv) Compound Rt-04

Organotellurium(IV) compounds have been reported to have multiple biological activities including cysteine protease-inhibitory activity, mainly cathepsin B. As cathepsin B is a highly predictive indicator for prognosis and diagnosis of cancer, a possible antitumor potential for these new compounds is expected. In this work, it was investigated the effectiveness of organotellurium(IV) RT-04 to produce lethal effects in the human promyelocytic leukaemia cell line HL60. Using the MTT tetrazolium reduction test, and trypan blue exclusion assay, the IC50 for the compound after 24 h incubation was 6.8 and 0.35 μM, respectively. Moreover, the compound was found to trigger apoptosis in HL60 cells, inducing DNA fragmentation and caspase-3, -6, and -9 activations. The apoptsosis-induced by RT-04 is probably related to the diminished Bcl-2 expression, observed by RT-PCR, in HL60-treated cells. In vivo studies demonstrated that the RT-04 treatment (2.76 mg/kg given for three consecutive days) produces no significant toxic effects for bone marrow and spleen CFU-GM. However, higher doses (5.0 and 10 mg/kg) produced a dose-dependent reduction in the number of CFU-GM of RT-04-treated mice. These results suggest that RT-04 is able to induce apoptosis in HL60 cells by Bcl-2 expression down-modulation. Further studies are necessary to better clarify the effects of this compound on bone marrow normal cells. © 2008 Elsevier Ltd. All rights reserved.46725402545Alonso, S., Minty, A., Bourlet, Y., Buckingham, M., Comparison of three actin-coding sequences in the mouseevolutionary relationships between the actin genes of warm-blooded vertebrates (1986) J. Mol. Evol., 23, pp. 11-22Baum, C., Fairbairn, L.J., Hildinger, M., Lashford, L.S., Hegewisch-Becker, S., Rafferty, J.A., New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells (1999) Expert Rev. Mol. Med., 12, pp. 1-28Brito, J.M., Borojevic, R., Liver granulomas in schistosomiasis: mast cell-dependent induction of SCF expression in hepatic satellite cells is mediated by TNF-alpha (1997) J. Leuk. Biol., 62, pp. 389-396Cao, G., Xiao, M., Sun, F., Xiao, X., Pei, W., Li, J., Graham, S.H., Chen, J., Cloning of a novel Apaf-1-interacting protein: a potent suppressor of apoptosis and ischemic neuronal cell death (2004) J. Neurosci., 24, pp. 6189-6201Chen, F., Vallyathan, V., Castranova, V., Shi, X., Cell apoptosis induced by carcinogenic metals (2001) Mol. Cell Biochem., 222, pp. 183-188Chen, M., Wang, J., Initiator caspases in apoptosis signaling pathways (2002) Apoptosis, 4, pp. 313-319Cohen, G.M., Caspases: the executioners of apoptosis (1997) Biochem. J., 326, pp. 1-16Cunha, R.L.O.R., Urano, M.E., Chagas, J.R., Almeida, P.C., Bincoletto, C., Tersariol, I.L.S., Comasseto, J.V., Tellurium-based cysteine protease inhibitors: evaluation of novel organotellurium(IV) compounds as inhibitors of human cathepsin B (2005) Bioorg. Med. Chem. Lett., 15, pp. 755-760Engman, L., Al-Maharik, N., McNaughton, M., Birmingham, A., Powis, G., Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells (2003) Bioorg. Med. Chem., 11, pp. 5091-5100Fesik, S.W., Promoting apoptosis as a strategy for cancer drugs discovery (2005) Nat. Rev., 5, pp. 876-885Frei, G.M., Lebenthal, I., Albeck, M., Albeck, A., Sredni, B., Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake (2007) Biochem. Pharmacol., 74, pp. 712-722Hanahan, D., Weinberg, R.A., The hallmarks of cancer (2000) Cell, 100, pp. 57-70Harrison, P.R., Lanfear, J., Wu, L., Fleming, J., McGarry, L., Blower, L., Chemopreventive and growth inhibitory effects of selenium (1997) Biomed. Environ. Sci., 10, pp. 235-245Jiang, X., Wang, X., Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1 (2000) J. Biol. Chem., 275, pp. 31199-31203Liu, X., Zou, H., Slaughter, C., Wang, X., DFF a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis (1997) Cell, 89, pp. 175-184Lovschall, H., Eiskjaer, M., Arenholt-Bindslev, D., Formaldehyde cytotoxicity in three human cell types assessed in three different assays (2002) Toxicol. In Vitro, 16, pp. 63-69Malerba, I., Casati, S., Diodovich, C., Parent-Massin, D., Gribaldo, L., Inhibition of CFU-E/BFU-E and CFU-GM colony growth by cyclophosphamide, 5-fluorouracil and taxol: development of a high-throughput in vitro method (2004) Toxicol. In Vitro, 3, pp. 293-300McNaughton, M., Engman, L., Birmingham, A., Powis, G., Cotgreave, I.A., Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth (2004) J. Med. Chem., 47, pp. 233-239Metcalf, D., (1984) Clonal Culture of Hemopoietic Cells: Techniques and Applications, , Elsevier, Amsterdam p. 167Minko, T., Kopecková, P., Kopecek, J., Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells (2001) J. Contr. Release, 71, pp. 227-237Mosmmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay (1983) J. Immunol. Meth., 65, pp. 55-63Newell, D.R., Silvester, J., McDowell, C., Burtles, S.S., The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies (2004) Eur. J. Cancer, 40, pp. 899-906. , Cancer Research UKNoda, Y., Suzuki, T., Kahara, A., Yotsuyanagi, A., Hasegawa, T., Hayshi, M., Sofuni, T., Okada, S., In vivo genotoxicity evaluation of dimethylarsinic in Muat™ mouse (2002) Mut. Ras. Gen Toxicol. Muagen., 513, pp. 205-212Nogueira, C.W., Zeni, G., Rocha, J.B., Organoselenium and organotellurium compounds: toxicology and pharmacology (2004) Chem. Rev., 104, pp. 6255-6285Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., An inhibitor of Bcl-2 family proteins induces regression of solid tumours (2005) Nature, 435, pp. 677-681Osorio, L.M., De Santiago, A., Aguilar-Santelises, M., Mellstedt, H., Jondal, M., CD6 ligation modulates Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM (1997) Blood, 89, pp. 2833-2841Pailard, F., Finot, F., Mouche, I., Perez, A., Vericat, J.A., Use of primary cultures of rat hepatocytes to predict toxicity in the early development of new chemical entities (1999) Toxicol. In vitro, 13, pp. 693-700Parent-Massin, D., Relevance of clonogenic assays in hematotoxicology (2001) Cell Biol. Toxicol., 17, pp. 87-94Pessina, A., Albella, B., Bayo, M., Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics (2003) Toxicol. Sci., 75, pp. 355-367Rinehart, J., Adjei, A.A., Lorusso, P.M., Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer (2004) J. Clin. Oncol., 22, pp. 4456-4462Rodriguez, J., Lazebnik, Y., Caspase-9 and APAF-1 form an active holoenzyme (1999) Genes Dev., 13, pp. 3179-3184Sailer, B.L., Liles, N., Dickerson, S., Sumners, S., Chasteen, T.G., Oraganotellurium compound toxicity in a promyelocytic cell line compared to non-tellurium-containing organic analog (2004) Toxicol. In vitro, 18, pp. 475-482Stewart, M.S., Davis, R.L., Walsh, L.P., Pence, B.C., Induction of differentiation and apoptosis by sodium selenite in human colonic carcinoma cells (HT29) (1997) Cancer Lett., 117, pp. 35-40Wei, M.C., Zong, W.X., Cheng, E.H., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death (2001) Science, 292, pp. 727-730Wieslander, E., Engman, L., Svensjö, E., Antioxidative properties of organotellurium compounds in cell systems (1998) Biochem. Pharmacol., 55, pp. 573-584Zeni, G., Chieffi, A., Cunha, R.L.O.R., Stefani, H.A., Zukerman-Schpector, J., Comasseto, J.V., (1999) Organometallics, 18, pp. 803-806Zimmermann, K.C., Bonzon, C., Green, D.R., The machinery of programmed cell death (2001) Pharmacol. Ther., 92, pp. 57-7